Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine

SJ Goldie, M Kohli, D Grima… - Journal of the …, 2004 - academic.oup.com
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …
被引用次数：753 相关文章

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

SJ Goldie, M Kohli, D Grima… - JNCI: Journal of the …, 2004 - search.ebscohost.com
Abstract < bold> Background: </bold> Human papillomavirus (HPV) vaccine may
be commercially available in a few years. We explored the clinical benefits and cost …

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

SJ Goldie, M Kohli, D Grima, MC Weinstein, TC Wright… - 2004 - cabidigitallibrary.org
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …
[PDF] academia.edu

[PDF][PDF] Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

SJ Goldie, M Kohli, D Grima, MC Weinstein… - Journal of the National …, 2004 - academia.edu
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

[引用][C] Projected clinical benefits and cost-effectiveness of a Human papillomavirus 16/18 vaccine

SJ GOLDIE, M KOHLI, D GRIMA… - Journal of the …, 2004 - pascal-francis.inist.fr
Projected clinical benefits and cost-effectiveness of a Human papillomavirus 16/18 vaccine
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

SJ Goldie, M Kohli, D Grima, MC Weinstein… - Journal of the …, 2004 - europepmc.org
Background Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …
[PDF] psu.edu

[PDF][PDF] Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

SJ Goldie, M Kohli, D Grima, MC Weinstein… - Journal of the National …, 2004 - Citeseer
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

[引用][C] Projected clinical benefits and Cost-effectiveness of a human papillomavirus 16/18 vaccine

G SJ - Journal of the National Cancer Institute, 2004 - cir.nii.ac.jp
Projected clinical benefits and Cost-effectiveness of a human papillomavirus 16/18 vaccine
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine

SJ Goldie, M Kohli, D Grima… - Journal of the …, 2004 - pubmed.ncbi.nlm.nih.gov
Background Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

SJ Goldie, M Kohli, D Grima, MC Weinstein… - Journal of the National …, 2004 - elibrary.ru
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …